Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Top Cited Papers
Open Access
- 26 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (2), 573-584
- https://doi.org/10.1038/s41375-020-0855-4
Abstract
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or safety. We further evaluated daratumumab’s effects on immune cells in whole blood samples of relapsed/refractory MM patients from both treatment arms of the phase 3 POLLUX study (lenalidomide/dexamethasone [Rd] or daratumumab plus Rd [D-Rd]) at baseline (D-Rd, 40; Rd, 45) and after 2 months on treatment (D-Rd, 31; Rd, 33) using cytometry by time-of-flight. We confirmed previous reports of NK cell reduction with D-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep responders to D-Rd, with a higher proportion of CD8+ versus CD4+ T cells. The expansion of CD8+ T cells correlated with clonality, indicating generation of adaptive immune response with D-Rd. D-Rd resulted in a higher proportion of effector memory T cells versus Rd. D-Rd reduced immunosuppressive CD38+ regulatory T cells. This study confirms daratumumab’s immunomodulatory MOA in combination with immunomodulatory drugs and provides further insight into immune cell changes and activation status following daratumumab-based therapy.Funding Information
- Janssen Global Services, LLC
This publication has 37 references indexed in Scilit:
- IL-2–dependent adaptive control of NK cell homeostasisThe Journal of Experimental Medicine, 2013
- Extracting a cellular hierarchy from high-dimensional cytometry data with SPADENature Biotechnology, 2011
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic ContinuumScience, 2011
- CD11b and CD27 reflect distinct population and functional specialization in human natural killer cellsImmunology, 2011
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- LAG-3 in Cancer ImmunotherapyPublished by Springer Science and Business Media LLC ,2010
- CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cellsEuropean Journal of Immunology, 2010
- Evaluation of a 12‐color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humansCytometry Part A, 2010
- Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodiesBlood, 2008
- CD8αα memory effector T cells descend directly from clonally expanded CD8α+βhigh TCRαβ T cells in vivoBlood, 2002